[1]
Armstrong PW, Pieske B, Anstrom KJ, Ezekowitz J, Hernandez AF, Butler J, Lam CSP, Ponikowski P, Voors AA, Jia G, McNulty SE, Patel MJ, Roessig L, Koglin J, O'Connor CM, VICTORIA Study Group. Vericiguat in Patients with Heart Failure and Reduced Ejection Fraction. The New England journal of medicine. 2020 May 14:382(20):1883-1893. doi: 10.1056/NEJMoa1915928. Epub 2020 Mar 28
[PubMed PMID: 32222134]
[2]
Iacoviello M, Palazzuoli A, Gronda E. Recent advances in pharmacological treatment of heart failure. European journal of clinical investigation. 2021 Nov:51(11):e13624. doi: 10.1111/eci.13624. Epub 2021 Jun 15
[PubMed PMID: 34043809]
Level 3 (low-level) evidence
[3]
Alsumali A,Lautsch D,Liu R,Patel D,Nanji S,Djatche LM, Budget Impact Analysis of Vericiguat for the Treatment of Chronic Heart Failure with Reduced Ejection Fraction Following a Worsening Event. Advances in therapy. 2021 May;
[PubMed PMID: 33860924]
Level 3 (low-level) evidence
[4]
Ezekowitz JA, O'Connor CM, Troughton RW, Alemayehu WG, Westerhout CM, Voors AA, Butler J, Lam CSP, Ponikowski P, Emdin M, Patel MJ, Pieske B, Roessig L, Hernandez AF, Armstrong PW. N-Terminal Pro-B-Type Natriuretic Peptide and Clinical Outcomes: Vericiguat Heart Failure With Reduced Ejection Fraction Study. JACC. Heart failure. 2020 Nov:8(11):931-939. doi: 10.1016/j.jchf.2020.08.008. Epub 2020 Oct 7
[PubMed PMID: 33039447]
Level 2 (mid-level) evidence
[5]
Markham A, Duggan S. Vericiguat: First Approval. Drugs. 2021 Apr:81(6):721-726. doi: 10.1007/s40265-021-01496-z. Epub
[PubMed PMID: 33770393]
[6]
Heidenreich PA, Bozkurt B, Aguilar D, Allen LA, Byun JJ, Colvin MM, Deswal A, Drazner MH, Dunlay SM, Evers LR, Fang JC, Fedson SE, Fonarow GC, Hayek SS, Hernandez AF, Khazanie P, Kittleson MM, Lee CS, Link MS, Milano CA, Nnacheta LC, Sandhu AT, Stevenson LW, Vardeny O, Vest AR, Yancy CW. 2022 AHA/ACC/HFSA Guideline for the Management of Heart Failure: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. Circulation. 2022 May 3:145(18):e895-e1032. doi: 10.1161/CIR.0000000000001063. Epub 2022 Apr 1
[PubMed PMID: 35363499]
Level 1 (high-level) evidence
[7]
Burnett JC Jr. Vericiguat - Another Victory for Targeting Cyclic GMP in Heart Failure. The New England journal of medicine. 2020 May 14:382(20):1952-1953. doi: 10.1056/NEJMe2006855. Epub
[PubMed PMID: 32402167]
[8]
Tsai EJ, Kass DA. Cyclic GMP signaling in cardiovascular pathophysiology and therapeutics. Pharmacology & therapeutics. 2009 Jun:122(3):216-38. doi: 10.1016/j.pharmthera.2009.02.009. Epub 2009 Mar 21
[PubMed PMID: 19306895]
[9]
Boettcher M, Gerisch M, Lobmeyer M, Besche N, Thomas D, Gerrits M, Lemmen J, Mueck W, Radtke M, Becker C. Metabolism and Pharmacokinetic Drug-Drug Interaction Profile of Vericiguat, A Soluble Guanylate Cyclase Stimulator: Results From Preclinical and Phase I Healthy Volunteer Studies. Clinical pharmacokinetics. 2020 Nov:59(11):1407-1418. doi: 10.1007/s40262-020-00895-x. Epub
[PubMed PMID: 32458378]
[10]
Armstrong PW,Lam CSP,Anstrom KJ,Ezekowitz J,Hernandez AF,O'Connor CM,Pieske B,Ponikowski P,Shah SJ,Solomon SD,Voors AA,She L,Vlajnic V,Carvalho F,Bamber L,Blaustein RO,Roessig L,Butler J,VITALITY-HFpEF Study Group., Effect of Vericiguat vs Placebo on Quality of Life in Patients With Heart Failure and Preserved Ejection Fraction: The VITALITY-HFpEF Randomized Clinical Trial. JAMA. 2020 Oct 20;
[PubMed PMID: 33079152]
Level 2 (mid-level) evidence
[11]
Boettcher M, Thomas D, Mueck W, Loewen S, Arens E, Yoshikawa K, Becker C. Safety, pharmacodynamic, and pharmacokinetic characterization of vericiguat: results from six phase I studies in healthy subjects. European journal of clinical pharmacology. 2021 Apr:77(4):527-537. doi: 10.1007/s00228-020-03023-7. Epub 2020 Oct 30
[PubMed PMID: 33125516]
[12]
Murphy SP,Ibrahim NE,Januzzi JL Jr, Heart Failure With Reduced Ejection Fraction: A Review. JAMA. 2020 Aug 4;
[PubMed PMID: 32749493]
[13]
Voors AA, Mulder H, Reyes E, Cowie MR, Lassus J, Hernandez AF, Ezekowitz JA, Butler J, O'Connor CM, Koglin J, Lam CSP, Pieske B, Roessig L, Ponikowski P, Anstrom KJ, Armstrong PW, VICTORIA Study Group. Renal function and the effects of vericiguat in patients with worsening heart failure with reduced ejection fraction: insights from the VICTORIA (Vericiguat Global Study in Subjects with HFrEF) trial. European journal of heart failure. 2021 Aug:23(8):1313-1321. doi: 10.1002/ejhf.2221. Epub 2021 Jun 3
[PubMed PMID: 33999486]
[14]
Lang NN,Dobbin SJH,Petrie MC, Vericiguat in worsening heart failure: agonising over, or celebrating, agonism in the VICTORIA trial. Cardiovascular research. 2020 Oct 1;
[PubMed PMID: 32980877]
[15]
Pieske B, Maggioni AP, Lam CSP, Pieske-Kraigher E, Filippatos G, Butler J, Ponikowski P, Shah SJ, Solomon SD, Scalise AV, Mueller K, Roessig L, Gheorghiade M. Vericiguat in patients with worsening chronic heart failure and preserved ejection fraction: results of the SOluble guanylate Cyclase stimulatoR in heArT failurE patientS with PRESERVED EF (SOCRATES-PRESERVED) study. European heart journal. 2017 Apr 14:38(15):1119-1127. doi: 10.1093/eurheartj/ehw593. Epub
[PubMed PMID: 28369340]
[16]
Heidenreich PA, Albert NM, Allen LA, Bluemke DA, Butler J, Fonarow GC, Ikonomidis JS, Khavjou O, Konstam MA, Maddox TM, Nichol G, Pham M, Piña IL, Trogdon JG, American Heart Association Advocacy Coordinating Committee, Council on Arteriosclerosis, Thrombosis and Vascular Biology, Council on Cardiovascular Radiology and Intervention, Council on Clinical Cardiology, Council on Epidemiology and Prevention, Stroke Council. Forecasting the impact of heart failure in the United States: a policy statement from the American Heart Association. Circulation. Heart failure. 2013 May:6(3):606-19. doi: 10.1161/HHF.0b013e318291329a. Epub 2013 Apr 24
[PubMed PMID: 23616602]
[17]
Gheorghiade M,Vaduganathan M,Fonarow GC,Bonow RO, Rehospitalization for heart failure: problems and perspectives. Journal of the American College of Cardiology. 2013 Jan 29
[PubMed PMID: 23219302]
Level 3 (low-level) evidence
[18]
Raat W, Smeets M, Janssens S, Vaes B. Impact of primary care involvement and setting on multidisciplinary heart failure management: a systematic review and meta-analysis. ESC heart failure. 2021 Apr:8(2):802-818. doi: 10.1002/ehf2.13152. Epub 2021 Jan 6
[PubMed PMID: 33405392]
Level 1 (high-level) evidence